1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities.

Abstract

In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse brain, there was no significant increase or decrease in the content of an endogenous amine, 1,2,3,4-tetrahydroisoquinoline (TIQ), which is well noted for inducing parkinsonism, whereas another endogenous amine, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTIQ), was markedly reduced. This result agrees with the finding in human idiopathic parkinsonianism, confirmed by our previous research. In addition, pretreatment with 1-MeTIQ completely prevented MPTP- or TIQ-inducing bradykinesia, a symptom of parkinsonism. This study confirmed that 1-MeTIQ plays an important role in preventing the pathogenesis of parkinsonism and is a possible leading compound of anti-parkinsonism agents.

• Authors: Y Tasaki, Y Makino, S Ohta, M Hirobe
• Journal: Journal of neurochemistry (J Neurochem) Vol. 57 Issue 6 Pg. 1940-3 (Dec 1991) ISSN: 0022-3042 [Print] England
• PMID: 1940911 (Publication Type: Journal Article)

Chemical References

• Isoquinolines
• Tetrahydroisoquinolines
• 1-methyl-1,2,3,4-tetrahydroisoquinoline
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Topics

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology)
• Animals
• Behavior, Animal (drug effects)
• Brain Chemistry
• Isoquinolines (analysis, pharmacology)
• Male
• Mice
• Mice, Inbred C57BL
• Motor Activity (drug effects)
• Parkinson Disease (psychology)
• Rats
• Tetrahydroisoquinolines
• Time Factors